Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company (BDX) Q3 2024 Earnings Call Transcript
Becton, Dickinson and Company (NYSE:BDX ) Q3 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer & President Chris DelOrefice - Executive Vice President & Chief Financial Officer Mike Garrison - President of the Medical Segment Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Rick Wise - Stifel Vijay Kumar - Evercore ISI Operator Hello and welcome to BD's Third Quarter Fiscal 2024 Earnings Conference Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website at investors.bd.com or by phone at 800-839-2385 for domestic calls and area code +1 402-220-7203 for international calls.
Compared to Estimates, Becton Dickinson (BDX) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton Dickinson (BDX) Q3 Earnings Beat Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.96 per share a year ago.
Becton Dickinson tops profit estimates on demand for drug-delivery devices
Becton Dickinson reported a better-than-expected third-quarter profit on Thursday, helped by strong demand for its drug-delivery devices.
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal third-quarter revenues.
Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Becton Dickinson (BDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
What Makes Becton Dickinson (BDX) a New Buy Stock
Becton Dickinson (BDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BDX vs. MMSI: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.
3 Healthcare Stocks to Buy Now to Profit From Aging Population Trends
If you can count, you may find healthcare stocks focused on the aging population to be a compelling opportunity. What do I mean?
US FDA flags shortage of Becton Dickinson's blood test tubes
The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' blood test tubes used in diagnosing bacterial and fungal infections.
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
BD's (BDX) robust product portfolio raises optimism about the stock.
